-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Buy on Oruka Therapeutics, Maintains $200 Price Target

Benzinga·10/27/2026 13:39:02
Guggenheim analyst Yatin Suneja reiterates Oruka Therapeutics (NASDAQ:ORKA) with a Buy and maintains $200 price target.